伐地那非联合舍曲林治疗早泄110例

目的观察伐地那非联合舍曲林治疗早泄的疗效并分析其安全性。方法选择医院收治的早泄患者230例,随机分成两组。对照组120例给予舍曲林50 mg,每日下午1次,连续1个月。治疗组110例在对照组治疗基础上联合使用伐地那非10 mg,性生活30 min前口服,每周2次,1个月为1个疗程。观察两组患者治疗前后的阴茎插入阴道后勃起维持时间(IELT)和不良反应发生情况,比较两组患者早泄情况的改善和患者及其性伴侣对双方性生活的满意度。结果经过治疗,两组IELT都比治疗前有显著性增加,对照组为(2.37±1.27)min,治疗组为(4.63±2.32)min;患者及其性伴侣治疗后的满意度对照组为38.33%、治疗组为63.64%,总满意度对照组为75.00%、治疗组为90.91%,差异均有统计学意义(P<0.05)。结论伐地那非联合舍曲林治疗早泄疗效显著,可有效延长IELT,提高患者及其性伴侣对性生活的满意度,不良反应少,值得临床推广。     

舍曲林联合碳酸锂治疗双相抑郁的疗效分析

目的 评价舍曲林联用碳酸锂治疗双相抑郁的疗效和安全性.方法 将符合CCMD-3(中国精神障碍分类和诊断标准第三版)双相障碍抑郁诊断标准的86例门诊或住院患者随机分为2组,每组43例.研究组用舍曲林合并碳酸锂,对照组用阿米替林合并碳酸锂,分别治疗8 w.分别于治疗前及治疗后第2、4、6、8 w用汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)、不良反应量表(TESS)比较两组的疗效和安全性.结果 治疗后第2、4 w末,2组HAMD、HAMA总分有显著性差异(P<0.05),研究组疗效优于对照组,第6、8 w末两组无显著性差异;治疗后第2、4、6、8 w末,2组TESS总分有显著性差异(P<0.05),研究组低于对照组;2组脱落率比较有显著性差异(P<0.05),研究组低于对照组.结论 舍曲林合并碳酸锂治疗双相抑郁疗效肯定,不良反应较少,依从性好.     

舍曲林联合特拉唑嗪治疗早泄临床研究

目的探讨舍曲林联合特拉唑嗪治疗早泄的疗效。方法将2011年8月至2013年9月收治的120例早泄患者随机分为观察组、对照组Ⅰ和对照组Ⅱ,各40例。观察组口服舍曲林,每次50 mg,每晚1次,连服4周,同时口服特拉唑嗪,每次2mg,每晚1次,连服4周;对照组Ⅰ口服舍曲林,每次50 mg,每晚1次,连服4周;对照组Ⅱ口服特拉唑嗪,每次2 mg,每晚1次,连服4周。观察各组治疗后射精潜伏期、配偶性生活满意率等。结果观察组患者治疗后射精潜伏期、配偶性生活满意率均优于对照组Ⅰ、Ⅱ,差异均有统计学意义（P〈0.05）。结论舍曲林联合特拉唑嗪治疗早泄临床疗效较好,预期效果满意,值得推荐使用。     

逍遥丸联合舍曲林治疗抑郁症临床疗效观察

目的对逍遥丸联合舍曲林治疗抑郁症临床疗效进行观察分析。方法 112例抑郁症患者随机分为治疗组和对照组各56例。其中对照组患者给予舍曲林进行治疗,治疗组患者给予舍曲林基础上予以逍遥丸进行治疗,疗程6周。以汉密尔顿抑郁量表(HAMD)、愈显率以及总有效率对两组患者在基线及治疗第2周末、第4周末、第6周末进行评定,以评价联合逍遥丸对抗抑郁药舍曲林的临床增效作用。结果两组患者经不同治疗后,与治疗前相比,两组患者HAMD评分均显著下降(P0.05),但较之于对照组,治疗组患者治疗后的HAMD总分具有显著性差异(P0.01)。两组经不同治疗后,与对照组相比,治疗组总有效率明显较高(P0.05)。结论逍遥丸联合舍曲林能够快速、有效地增强抗抑郁药舍曲林的临床疗效,改善临床症状,值得临床推广。     

舍曲林联合认知行为疗法治疗青少年抑郁症的对照研究

目的探讨舍曲林联合认知行为疗法治疗青少年抑郁症的疗效和安全性。方法将130例符合《中国精神疾病分类方案与诊断标准》第3版(CCMD-3)抑郁症诊断标准的青少年患者随机分为2组(各65例):治疗组应用舍曲林联合认知行为疗法(舍曲林50～200 mg·d~(-1),认知行为疗法每周一次),对照组单一服用舍曲林(50～200 mg·d~(-1))治疗。疗程8 wk。以汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)和症状自评量表(SCL-90)于治疗前和治疗2、4、6、8 wk末分别评定疗效。结果治疗组和对照组分别脱落4例和6例,实际共完成120例。与治疗前相比,2组治疗、wk 2末HAMD、HAMA评分均有显著下降(P<0.05,P<0.01),SCL-90评分无显著变化(P>0.05);2组HAMD、HAMA和SCL-90评分于wk 4、6、8末均显著下降(P<0.01)。2组间相比,wk 4、6、8末HAMD、HAMA和SCL-90评分均有非常显著差异(P<0.01)。2组不良反应主要为恶心、厌食、头晕,组间不良反应发生率无显著差异(x~2=0.512,P=0.474)。结论舍曲林联合认知行为疗法治疗青少年抑郁症较舍曲林单一治疗疗效更佳,安全性相当。     

奥氮平联合舍曲林对抑郁症患者皮肤交感反应的影响

目的探讨奥氮平联合舍曲林对抑郁症患者的临床疗效及对皮肤交感反应(SSR)的影响。方法60例诊断为抑郁症的患者按最小不平衡指数法将患者分为联合组与舍曲林组,各30例。选取同期在本院门诊的健康志愿者共30例为对照组。舍曲林组采用盐酸舍曲林片治疗,联合组在舍曲林组的基础上睡前口服奥氮平片治疗。对照组不做任何治疗。比较两治疗组临床疗效、治疗前及治疗4周后的汉密尔顿抑郁量表(HAMD)评分、三组SSR潜伏期和波幅及舍曲林组和联合组不良反应发生情况。结果联合组治疗总有效率为93.33%显著高于舍曲林组的70.00%,差异具有统计学意义(P<0.05)。治疗后,两组患者的HAMD评分均低于本组治疗前,且联合组HAMD评分为(12.1±3.9)分低于舍曲林组的(14.6±4.3)分,差异均具有统计学意义(P<0.05)。治疗前舍曲林组和联合组SSR的起始波潜伏期均明显长于对照组,而波幅均明显低于对照组,差异均具有统计学意义(P<0.05)。治疗后舍曲林组和联合组的SSR起始波潜伏期仍高于对照组,而波幅仍低于对照组,差异均具有统计学意义(P<0.05)。舍曲林组和联合组治疗后SSR的起始波潜伏期均短于本组治疗前,波幅均高于本组治疗前;治疗后联合组SSR的起始波潜伏期显著短于舍曲林组,波幅显著高于舍曲林组,差异均具有统计学意义(P<0.05)。舍曲林组和联合组不良反应发生率比较,差异无统计学意义(P>0.05)。结论奥氮平联合舍曲林治疗抑郁症临床效果显著,且对患者自主神经功能的改善作用优于单用舍曲林治疗。     

舍曲林合并心理治疗对青少年抑郁的疗效研究

目的探讨舍曲林合并个别心理治疗对青少年抑郁症的疗效。方法将132例青少年抑郁症患者随机分为2组：舍曲林治疗组（药物组）、舍曲林合并心理治疗组（综合组）,分别采用汉密尔顿抑郁量表（HAMD）、贝克抑郁自评问卷（BDI）在治疗前、治疗4周末、8周末进行评定。结果两组治疗4周末和8周末的HAMD、BDI评分均显著降低（P〈0.01）,但以综合组下降明显。综合组在治疗4周末和8周末的BDI评分与对照组相比,差异有统计学意义（P〈0.01）;综合组在8周末的HAMD评分与4周末相比,差异有统计学意义（P〈0.01）。结论舍曲林合用心理治疗对青少年抑郁症的疗效优于单用舍曲林。家长教育是对青少年心理治疗的一种有益尝试。     

早泄患者的药物治疗方案研究

目的比较舍曲林联合多沙唑嗪及他达拉非治疗早泄的疗效及不良反应。方法选择2013年10月~2014年5月在我院收治的早泄患者240例,将患者随机分为A、B、C三组,每组80例。三组均服用服用舍曲林50mg,每日下午1次。B组患者加服多沙唑嗪4mg,1次/d(性生活前8~9h服用);C组患者于性生活前1h加服他达拉非20mg。连续治疗12周为1个疗程,记录三组患者治疗前后的平均阴道内射精潜伏期、性生活满意度和不良反应。结果治疗12周后,A、B、C三组患者的射精潜伏期均有所提高(P<0.05),B、C组患者射精潜伏期明显高于A组,差异有统计学意义(P<0.05),B、C组差异无统计学意义(P>0.05)。治疗后,患者对性生活满意度均有显著性提高(P<0.05),B、C两组患者的满意率明显高于A组(P<0.05),差异具有统计学意义。B、C组患者的不良反应发生率显著高于A组,差异有统计学意义(P<0.05)。结论舍曲林联合多沙唑嗪或他达拉非治疗早泄比单独使用舍曲林在加长射精潜伏期、提高性生活满意度方面更加有效,但是联合用药也会导致一定的不良反应,如胃部不适、头疼、性欲下降等。     

盐酸舍曲林联合坦索罗辛治疗早泄并发焦虑50例

目的 评价盐酸舍曲林片联合坦索罗辛缓释胶囊治疗早泄并发焦虑的临床疗效. 方法 将100例早泄并发焦虑患者随机分为两组,各50例,治疗组口服盐酸舍曲林片,每晚50 mg;坦索罗辛缓释胶囊,每晚0.2 mg. 对照组口服盐酸舍曲林片,用法用量同治疗组. 均4周为1个疗程. 记录并分析患者治疗前后平均阴道内射精潜伏时间、双方性交满意度及焦虑症状评分. 结果 治疗组、对照组患者平均阴道内射精潜伏时间、双方性交满意度及焦虑症状评分较治疗前差异有统计学意义(P<0.05或P<0.01). 治疗组治疗后平均阴道内射精潜伏时间延长,双方性交满意度提高,均较对照组差异有统计学意义(P<0.05或P<0.01). 结论 盐酸舍曲林片联合坦索罗辛缓释胶囊可明显延长早泄并焦虑患者平均阴道内射精潜伏时间,提高性交满意度,缓解焦虑,且优于单纯应用盐酸舍曲林片.     

心理干预联合舍曲林治疗老年抑郁症65例效果观察

目的:观察心理干预联合舍曲林治疗老年抑郁症的效果.方法:将65例老年抑郁症患者随机分成两组,即研究组32例(采用心理干预联合舍曲林)和对照组33例(单用舍曲林),系统治疗8周;采用汉密顿抑郁量表(HAMD)评定疗效,不良反应症状量表(TESS)评定不良反应.结果:治疗第8周末,研究组总有效率为93.8%.对照组75.8%,两组差异有统计学意义(x2=4.62,P<0.05);两组HAMD评分均较治疗前显著下降(P<0.01),研究组在2、6、8周末较对照组下降更显著(P<0.05,P<0.01).两组治疗后各时段TESS评分比较差异均无统计学意义(P>0.05).结论:心理干预联合舍曲林治疗老年抑郁症比单纯服用舍曲林起效快,疗效好.     

伐地那非联合表面麻醉剂治疗勃起功能障碍伴早泄的临床研究

目的探讨伐地那非联合表面麻醉剂治疗勃起功能障碍(ED)伴有早泄患者的临床效果和安全性。方法 60例诊断为合并ED的早泄患者,按需每次服用伐地那非20 mg,并将复方利多卡因乳膏于性交前均匀涂搽龟头处,共治疗12周。以阴道内射精潜伏期评价早泄治疗效果,并评估ED的总体疗效和治疗满意度,比较治疗前后的国际勃起功能指数-5(IIEF-5)评分。结果治疗12周后,38例患者报告早泄有好转,有效率达63.3%,平均阴道内射精潜伏时间(IEL-T)由治疗前(0.43±0.31)min延长至(4.2±2.1)min;性交满意度评分由(7.6±2.5)分上升至(10.2±1.9)分,差异均有显著性(P<0.01)。勃起功能改善者共46例,总改善率为76.7%,IIEF-5评分从治疗前的平均11.2(11.2±4.9)分上升到治疗后的平均19.1(19.1±4.1)分,差异有显著性(P<0.01)。不良反应共有8例(13.3%),均为轻度或中度的,未经处理即自行缓解。结论对合并ED的早泄病人,伐地那非联合表面麻醉剂能安全有效地改善其勃起功能,并能显著改善其早泄症状。     

Safety and efficacy of escitalopram in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study

PURPOSE: To evaluate the efficacy and safety of most selective serotonin reuptake inhibitor drug, escitalopram, in delaying ejaculation in patients with premature ejaculation (PE). MATERIALS AND METHODS: A total of 276 married men (mean age, 34.4 years) with PE were randomly assigned to receive 10 mg of escitalopram (n = 138; Group 1) or placebo (n = 138; Group 2) for 12 weeks. Pretreatment evaluation included history and physical examination, intravaginal ejaculatory latency time (IELT), International Index of Erectile Function (IIEF), and Meares-Stamey test. The efficacy of 2 treatments was assessed every 2 weeks during treatment, at the end of study, and in 3- and 6-month follow-up after cessation of treatment. RESULTS: At the end of 12-week treatment, the escitalopram group had a 4.9-fold (95% confidence interval [CI], 3.14-6.12) increase of the geometric mean IELT, whereas after placebo, the geometric mean IELT did not increase significantly (1.4-fold increase; 95% CI, 0.86-1.68; P = 0.001). Baseline mean intercourse satisfaction domain values of IIEF 10 and 11 reached to 16 and 10 at 12-week treatment in Groups 1 and 2, respectively (P = 0.01). At the end of 6-month follow-up period, the geometric mean IELT in escitalopram and placebo group demonstrated 3.1- (95% CI, 2.16-4.4) and 1.3-fold (95% CI, 0.78-1.62) increase, respectively (P = 0.001). Three- and 6-month intercourse satisfaction domain values of IIEF were 15 and 14 in Groups 1 and 10 and 10 (P = 0.01) in Group 2, respectively. Mean number of adverse events was 22 for escitalopram and 9 for placebo (P = 0.04). CONCLUSIONS: Oral escitalopram is an effective treatment for PE with long-term benefit for the patient after it is withdrawn. Further studies are required to draw final conclusions on the efficacy of this drug in PE.     

性感集中训练法联合西地那非治疗早泄的临床观察

目的 观察应用性感集中训练法联合西地那非治疗早泄的疗效.方法 32例早泄患者应用性感集中训练法治疗4周,并于性交前0.5～1 h口服西地那非50 mg,观察患者治疗前后、停药后4周及8周的阴道内射精潜伏期时间、阴道内射精潜伏期评分、患者性生活满意度、配偶性生活满意度.结果 治疗后,阴道内射精潜伏期时间及其评分、患者性生活满意度、配偶性生活满意度与治疗前比较,差异有统计学意义[(3.84±0.42)min比(0.72 ±0.20) min,(1.86±0.28)分比(2.52±0.21)分,(9.8±1.3)分比(4.8±1.5)分,(9.5±1.2)分比(4.6±1.3)分,P＜0.01或P＜0.05],停药后4、8周上述指标与治疗后比较,差异均无统计学意义(P＞0.05).结论 性感集中训练法联合西地那非对早泄有较好的治疗效果,能延长阴道内射精潜伏期、提高患者夫妻双方性生活满意度,且治疗效果稳定、复发率低.     

Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study.

The aim of the study was to evaluate the efficacy and safety of a selective serotonin reuptake inhibitor (SSRI) drug dapoxetine in delaying ejaculation in patients with premature ejaculation (PE). A total of 212 potent men with PE were randomly assigned to receive 30 mg orally dapoxetine (group 1, N=106) twice daily or similar regimen of placebo (group 2, N=106) during a 12-week period for each agent. Pretreatment evaluation included history and physical examination, geometric mean intravaginal ejaculatory latency time (IELT, primary outcome measure), and International Index of Erectile Function (IIEF). The efficacy of two treatments was assessed every 2 weeks during treatment, at the end of study, and in 3-month follow-up after cessation of treatment. We measured geometric mean IELT. Thus, the IELT values were logarithmically transformed before statistical analysis, and the results are reported as fold increases from baseline with associated 95% confidence intervals (CI). The independent sample two-tailed t-test was used to compare the IELTs. At the end of 12-week treatment, the dapoxetine group had a 2.9- (95% CI, 1.84-4.16) fold increase of the geometric mean IELT, while after placebo the geometric mean IELT did not increase significantly (1.4-fold increase; 95% CI, 0.84-1.63) (p=0.001). The mean weekly intercourse episodes increased from pretreatment values of 1.16 and 1.14 to 2.2 and 1.4, for dapoxetine and placebo, respectively (p=0.04). Baseline mean intercourse satisfaction domain values of IIEF, 12 and 11, reached to 16 and 10 at the 12-week treatment in groups 1 and 2, respectively (p=0.04). At the end of 3-month follow-up period, the geometric mean IELT in dapoxetine and placebo group demonstrated 1.4- (95% CI, 0.66-1.46) and 1.3- (95% CI, 0.77-1.63) fold increase, respectively (p=0.1). Three-month intercourse satisfaction domain value of IIEF was 11 in group 1 and 10 in group 2 (p=0.1). Mean number of adverse events was 19 for dapoxetine and 7 for placebo (p=0.02). Dapoxetine has moderately better results in terms of IELT and intercourse satisfaction vs placebo without long-term benefit for the patient after it is withdrawn. Further studies are necessary to draw final conclusions on the efficacy of this drug in PE.     

氟西汀联合性感集中训练法治疗早泄疗效观察

目的观察氟西汀联合性感集中训练法治疗早泄（PE）的临床疗效,为治疗该病提供更多参考。方法将2013年8月至2014年2月该院收治的69例PE患者随机分为治疗组（35例）和对照组（34例）。对照组采用性感集中训练法,治疗组在对照组基础上服用氟西汀20 mg/d,疗程4周。比较两组患者治疗后性生活满意度。结果治疗组患者治疗后性生活满意度好转率和显效率[65.71%（23/35）、22.86%（8/35）]优于对照组[52.94%（18/34）、2.94%（1/34）],差异均有统计学意义（P〈0.05）。结论氟西汀联合性感集中训练法治疗PE临床有效率较高,不良反应较少。     

Vardenafil

Vardenafil selectively inhibits phosphodiesterase type 5 (PDE5), an enzyme which hydrolyses cyclic guanosine monophosphate in the cavernosum tissue of the penis. Inhibition of PDE5 results in increased arterial blood flow leading to enlargement of the corpus cavernosum. Because of the increased tumescence, veins are compressed between the corpus cavernosum and the tunica albuginea, resulting in an erection. Vardenafil has a high bioavailabilty and is rapidly absorbed. An erection of >60% rigidity was maintained for approximately twice as long following visual stimulation in patients treated with vardenafil 10 or 20mg than in recipients of placebo. In a large, placebo-controlled trial in patients with mild to severe erectile dysfunction (ED), vardenafil 5, 10 or 20mg taken as needed over a 12-week period significantly improved the scores in questions 3 and 4 of the International Index of Erectile Function (IIEF). The rate of successful attempts at intercourse with ejaculation was also significantly higher with vardenafil (71 to 75%) than in the placebo group (39.5%), and significantly more patients treated with vardenafil than placebo responded 'yes' to a Global Assessment Question (GAQ) asking if treatment had improved erections. In a 26-week trial in 736 men with ED of varied aetiologies and severity patients receiving vardenafil 5, 10 or 20mg experienced significantly improved erections with 85% of vardenafil 20mg recipients reporting improved erectile function (assessed using the GAQ) compared with 28% of placebo recipients. Treatment with vardenafil also significantly improved scores in response to questions 3 and 4 of the IIEF compared with placebo. A 12-week trial in 452 men with ED associated with diabetes mellitus demonstrated that treatment with vardenafil 20mg compared with placebo significantly improved IIEF erectile function domain scores and the rate of positive responders to the erectile improvement GAQ. Similar results were reported in a placebo-controlled trial of vardenafil 10 to 20mg involving 440 patients with ED after radical prostatectomy. Adverse events associated with vardenafil were those commonly associated with PDE5 inhibitors: headache, flushing, dyspepsia and rhinitis. These were mostly dose-dependent and mild to moderate in intensity.     

舍曲林与西酞普兰治疗帕金森病合并抑郁的差别的临床研究

目的：研究舍曲林、西酞普兰治疗帕金森病合并抑郁的疗效及安全性。方法帕金森病合并抑郁患者随机分为舍曲林治疗组及西酞普兰治疗组,采用抑郁自评量表（SDS）在治疗前、治疗6周及治疗12周评价疗效。结果西酞普兰组早期起效快于舍曲林组,但12周后有效率无明显差别,两组均未见严重不良反应。结论常规剂量的舍曲林和西酞普兰治疗帕金森病伴发抑郁均安全有效。     

Once-daily high-dose pindolol for paroxetine-refractory premature ejaculation: a double-blind, placebo-controlled and randomized study

PURPOSE: To evaluate the efficacy and safety of pindolol 7.5 mg/d in delaying of ejaculation in paroxetine-refractory patients. MATERIALS AND METHODS: Eighty-six married men (mean age, 33 years) with premature ejaculation unresponsive to paroxetine 20 mg/d given for 2 months or longer were randomized to receive 7.5 mg pindolol (n = 44) (group 1) (PXT + POL) or placebo (n = 42) (group 2) (PXT + PBO) for 6 weeks, while continuing paroxetine. After 6 weeks, all patients received paroxetine and placebo and were followed for 3 further weeks in a single-blind manner. Pretreatment evaluation included history and physical examination, mean intravaginal ejaculatory latency time (IELT), International Index of Erectile Function (IIEF), and Meares-Stamey test. The efficacy of 2 treatments was assessed every 1 week during treatment and, at the end of study, using responses to IIEF, IELT evaluation, mean intercourse satisfaction domain, mean weekly coitus episodes, and adverse drug effects. RESULTS: Seventy-seven (89.5%) completed the whole treatment schedule. At the end of 6-week treatment period, the IELT after paroxetine-pindolol and paroxetine-placebo gradually increased from mean 48 and 41 seconds to approximately 188 and 58 seconds, respectively (P = 0.001). The mean weekly intercourse episodes increased from pretreatment values of 1.5 and 1.5 to 2.7 and 1.7, for groups PXT + POL and PXT + PBO, respectively (P = 0.01). Baseline mean intercourse satisfaction domain values of IIEF 12 and 11 reached to 16 and 11 at 6-week treatment in PXT + POL and PXT + PBO groups, respectively (P = 0.01). Upon discontinuing pindolol, all outcome measures returned to baseline values rapidly. The incidence of side effects with paroxetine-pindolol was significantly higher (P = 0.04). CONCLUSIONS: These findings support that a single high dose of pindolol (7.5 mg) is an effective augmentation strategy in paroxetine-refractory patients.     

氯丙咪嗪联合复方玄驹胶囊治疗早泄疗效观察

目的:观察氯丙咪嗪联合复方玄驹胶囊治疗早泄的疗效.方法:405例早泄患者,分为治疗组(205例)和对照组(200例).两组患者均服用氯丙咪嗪,治疗组同时服用复方玄驹胶囊.治疗4周后观察性生活满意度.结果:治疗后治疗组性生活满意度的治愈率和改善率分别为21.9%和56%,均显著优于对照组.结论:氯丙咪嗪联合复方玄驹胶囊治疗早泄有明显疗效.     

人参果总皂苷(SFPG)联合舍曲林治疗高血压病合并抑郁症的疗效及副反应观察

摘要 目的 探讨人参果总皂苷(SFPG)联合舍曲林治疗高血压病合并抑郁症的临床疗效及安全性。方法 选取88例高血压病合并抑郁症患者随机分为SFPG加舍曲林组和舍曲林单用组,在治疗前和用药后2,4,6周用HAMD评分量表评定其疗效,以TESS量表评定并观察两者的副作用。结果 治疗6周末,与舍曲林单用组相比,联合组HAMD评分的减分率有显著性差异,且不良反应明显减少(P<0. 01) ,合用组有效率为93.00%,单用组有效率为77.80%,两比较差异有显著性(P<0. 01)。两组患者用药6周TESS评分比较有显著性差异 (P<0. 01)。结论 SFPG对高血压病合并抑郁症的治疗有显著的辅助作用,副反应较单用舍曲林减少。